Critical Path Opportunities List Previewed By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Critical Path opportunities list will emphasize development in disease areas with “urgent needs” and “at risk” patient populations, CDER Director Galson says.